In this study, lafutidine effervescent tablets were developed to replace traditional lafutidine tablets in the treatment of gastric and duodenal ulcers, where rapid start of action is advantageous in controlling gastric and duodenal ulcers and aids in bioavailability. Use various acid sources, such as citric acid (F1-F3), tartaric acid (F4-F6), fumaric acid (F7-F9), and carbonate sources (such as sodium bicarbonate) to prepare effervescent tablets using direct compression. The produced tablets are tested for properties after compression, like hardness, friability, thickness, weight change, drug content, CO2 content, in vitro disintegration time and stability tests. Drug excipient compatibility was investigated using FT-IR and DSC in the preformulation research, suggesting that medicines, acids, bases, and other excipients are compatible. Pre-compressional parameter values were within specified limits, indicating satisfactory free-flowing properties. Except for formulations F1-F3, all post-compressional parameters were tested, and the findings were within acceptable ranges. F11 had the fastest effervescence and disintegration of all the formulations. The produced lafutidine effervescent tablets were stable and kept their medicinal characteristics for 3 months, according to stability testing of the optimised formulation F11. According to the findings of this study, lafutidine effervescent tablets are a viable formulation for the treatment of ulcers.